mrna-derived ido/pd-l1-targeted vaccine mrna-4359
Generic: mRNA-derived IDO/PD-L1-targeted Vaccine mRNA-4359
mrna-derived ido/pd-l1-targeted vaccine mrna-4359: 1 clinical trial tracked.
mrna-derived ido/pd-l1-targeted vaccine mrna-4359 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mrna-derived ido/pd-l1-targeted vaccine mrna-4359, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Primary endpoint: Arms 1a and 1b: Maximum Tolerated Dose (MTD) or Recommended Dose for Expansion (RDE) of mRNA-4359
Interventionalopen361 targetStarted 2022-09Completion 2032-0239 sites · Australia, Germany, Italy, Poland…ModernaTX, Inc.